Apoptone

DB06307InvestigationalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified).

Mechanism: HE3235 is a second generation antitumor agent that causes apoptosis (cell death). HE3235 inhibits the BCL2 gene which translates proteins that prevent apoptosis and stimulates the expression proteins that induce apoptosis. HE3235 also downregulates the gene that codes for the multi-drug resistant protein ABCG2 (BCRP1 – Breast Cancer Resistance Protein1).
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₂₁H₃₂O₂ · 316.485 g/mol (avg)
Code names: HE-3235

Resolves to

Compound

Structure

InChIKeyCKAXZOYFIHQCBN-JRRMKBMNSA-NSMILESC[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Apoptone, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.